nct_id,start_date,phase,study_type,brief_title,gender,minimum_age,healthy_volunteers,primary_purpose,allocation,masking,int_and_obs_model
NCT04366830,,,Expanded Access,"Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19 Infection",All,18.0,,,,,
NCT04372602,2020_27,Phase 2,Interventional,Duvelisib to Combat COVID-19,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04381013,2020_22,,Interventional,Emergency Ventilator Splitting Between Two or More Patients (COVID-19),All,18.0,No,Device Feasibility,Non-Randomized,None (Open Label),Sequential Assignment
NCT04377308,2020_18,Phase 4,Interventional,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,All,18.0,Accepts Healthy Volunteers,Treatment,Non-Randomized,None (Open Label),Parallel Assignment
NCT04353401,2020_18,,Observational,WGS ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS,All,18.0,No,,,,Cohort
NCT04338828,2020_18,Phase 2,Interventional,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,All,18.0,No,Treatment,Randomized,Triple,Parallel Assignment
NCT04334512,2020_18,Phase 2,Interventional,A Study of Quintuple Therapy to Treat COVID-19 Infection,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04352634,2020_17,,Observational,The Covid-19 HEalth caRe wOrkErS (HEROES) Study,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04362150,2020_17,,Observational,Long-term Impact of Infection With Novel Coronavirus (COVID-19),All,18.0,No,,,,Cohort
NCT04367857,2020_16,,Observational [Patient Registry],ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04338126,2020_16,Phase 2,Interventional,Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients,All,19.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04369742,2020_16,Phase 2,Interventional,Treating COVID-19 With Hydroxychloroquine (TEACH),All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04380870,2020_15,,Observational,Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19,All,18.0,No,,,,Ecologic or Community
NCT04353037,2020_15,Phase 2,Interventional,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,All,50.0,Accepts Healthy Volunteers,Treatment,Randomized,Double,Parallel Assignment
NCT04320862,2020_14,,Observational,COVID-19 Pandemic Response Network,All,,Accepts Healthy Volunteers,,,,Cohort
NCT04334382,2020_14,Phase 3,Interventional,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,All,45.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04283461,2020_12,Phase 1,Interventional,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),All,18.0,Accepts Healthy Volunteers,Prevention,Non-Randomized,None (Open Label),Sequential Assignment
NCT04372368,,,Expanded Access,Convalescent Plasma for the Treatment of Patients With COVID-19,All,18.0,,,,,
NCT04380948,2020_31,Phase 1,Interventional,"A Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Enhance Immune Clearance of SARS-CoV-2",All,18.0,No,Treatment,Randomized,Triple,Parallel Assignment
NCT04323761,,,Expanded Access,Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19),All,12.0,,,,,
NCT04358211,,,Expanded Access,Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19,All,18.0,,,,,
NCT04374370,,,Expanded Access,SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP),All,6.0,,,,,
NCT04338360,,,Expanded Access,Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19,All,18.0,,,,,
NCT04338347,,,Expanded Access,CAP-1002 in Severe COVID-19 Disease,All,18.0,,,,,
NCT04360551,2020_27,Phase 2,Interventional,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,All,18.0,No,Treatment,Randomized,Triple,Parallel Assignment
NCT04320511,2020_27,,Observational,Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2,All,18.0,No,,,,Cohort
NCT04354714,2020_27,Phase 2,Interventional,Ruxolitinib to Combat COVID-19,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04344184,2020_27,Phase 2,Interventional,Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI),All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04374279,2020_27,Phase 2,Interventional,Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04340232,2020_27,Phase 2/Phase 3,Interventional,Safety and Efficacy of Baricitinib for COVID-19,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04378803,2020_25,,Interventional,Mindfulness Training for Seniors,All,65.0,Accepts Healthy Volunteers,Supportive Care,Randomized,None (Open Label),Crossover Assignment
NCT04376710,2020_23,,Observational,Surgical Telemedicine in the COVID-19 Pandemic Era,All,0.0,Accepts Healthy Volunteers,,,,Other
NCT04371640,2020_22,Phase 1,Interventional,Sirolimus in COVID-19 Phase 1,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04353206,2020_22,Early Phase 1,Interventional,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04377100,2020_20,,Interventional,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,All,18.0,No,Basic Science,,None (Open Label),Single Group Assignment
NCT04345601,2020_22,Early Phase 1,Interventional,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04344587,2020_22,,Interventional,COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning,All,18.0,No,Supportive Care,Randomized,None (Open Label),Parallel Assignment
NCT04364802,2020_22,Phase 2,Interventional,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,All,18.0,Accepts Healthy Volunteers,Prevention,Non-Randomized,None (Open Label),Parallel Assignment
NCT04369599,2020_22,,Interventional,Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04336774,2020_22,,Interventional,CAPTION AI to Minimize Risk of COVID Exposure,All,18.0,No,Diagnostic,,None (Open Label),Single Group Assignment
NCT04367831,2020_22,Phase 4,Interventional,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,All,18.0,No,Treatment,Randomized,Single,Parallel Assignment
NCT04367077,2020_22,Phase 2/Phase 3,Interventional,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),All,18.0,No,Treatment,Randomized,Quadruple,Sequential Assignment
NCT04333732,2020_22,Phase 3,Interventional,CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION,All,18.0,No,Prevention,Randomized,Double,Parallel Assignment
NCT04340479,2020_22,,Observational [Patient Registry],The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation,All,,Accepts Healthy Volunteers,,,,Cohort
NCT04365257,2020_22,Phase 2,Interventional,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),All,45.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04347954,2020_22,Phase 1/Phase 2,Interventional,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04312997,2020_22,Phase 2,Interventional,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04313023,2020_22,Phase 2,Interventional,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,All,18.0,No,Prevention,Randomized,Quadruple,Parallel Assignment
NCT04381052,2020_22,Phase 2,Interventional,Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04355767,2020_22,Phase 2,Interventional,Convalescent Plasma vs. Placebo in Emergency Room Patients With COVID-19,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04349631,2020_19,Phase 2,Interventional,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,All,,Accepts Healthy Volunteers,Prevention,,None (Open Label),Single Group Assignment
NCT04347538,2020_22,,Interventional,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04376593,2020_22,Early Phase 1,Interventional,PET/CT Imaging in COVID-19 Patients,All,18.0,No,Diagnostic,,None (Open Label),Single Group Assignment
NCT04363866,2020_22,Phase 4,Interventional,A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19),All,18.0,No,Treatment,Randomized,Single,Parallel Assignment
NCT04361552,2020_22,Phase 3,Interventional,Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection),All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04379518,2020_22,Phase 1/Phase 2,Interventional,Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients,All,18.0,No,Supportive Care,,None (Open Label),Single Group Assignment
NCT04332107,2020_21,Phase 3,Interventional,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04343976,2020_20,Phase 2,Interventional,Pegylated Interferon Lambda Treatment for COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04362189,2020_20,Phase 2,Interventional,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,All,,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04354155,2020_20,Phase 2,Interventional,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,All,,No,Prevention,,None (Open Label),Single Group Assignment
NCT04344977,2020_20,,Observational,Collection of Anti-SARS-CoV-2 Immune Plasma,All,18.0,Accepts Healthy Volunteers,,,,Case-Only
NCT04339790,2020_20,,Observational,Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04371432,2020_20,,Observational,Genetics of COVID-19 Susceptibility and Manifestations,All,3.0,No,,,,Case-Control
NCT04334954,2020_20,,Observational,SARS-COV2 Pandemic Serosurvey and Blood Sampling,All,18.0,Accepts Healthy Volunteers,,,,Case-Only
NCT04380688,2020_20,Phase 2,Interventional,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04377620,2020_19,Phase 3,Interventional,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04379492,2020_19,Phase 2,Interventional,A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04368234,2020_19,,Observational [Patient Registry],Duke COVID-19 Shared Data and Specimen Repository,All,,No,,,,Cohort
NCT04374565,2020_19,Phase 2,Interventional,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04374552,2020_19,Phase 2,Interventional,Asymptomatic COVID-19 Trial,All,20.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04379284,2020_19,,Observational,Risks of COVID19 in the Pregnant Population,Female,18.0,No,,,,Case-Only
NCT04334460,2020_19,Phase 2,Interventional,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04363346,2020_19,Phase 1,Interventional,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,All,18.0,No,Treatment,Non-Randomized,None (Open Label),Sequential Assignment
NCT04378777,2020_18,,Observational,Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC),All,18.0,No,,,,Cohort
NCT04377659,2020_18,Phase 2,Interventional,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04377412,2020_18,,Observational,Risk Factors for Anxiety and Depression Among Pregnant Women During the COVID-19 Pandemic,Female,18.0,Accepts Healthy Volunteers,,,,Ecologic or Community
NCT04375761,2020_18,,Observational,COVID-19: Human Epidemiology and Response to SARS-CoV-2,All,,Accepts Healthy Volunteers,,,,Family-Based
NCT04374786,2020_18,,Interventional,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,All,18.0,Accepts Healthy Volunteers,Supportive Care,,None (Open Label),Single Group Assignment
NCT04374461,2020_18,Phase 2,Interventional,A Study of N-acetylcysteine in Patients With COVID-19 Infection,All,18.0,No,Treatment,Non-Randomized,None (Open Label),Parallel Assignment
NCT04374019,2020_18,Phase 2,Interventional,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04372628,2020_18,Phase 2,Interventional,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,All,18.0,No,Treatment,Randomized,Triple,Sequential Assignment
NCT04338074,2020_16,Phase 2,Interventional,TXA and Corona Virus 2019 (COVID19) in Outpatients,All,19.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04366986,2020_18,,Observational [Patient Registry],International Registry of Coronavirus (COVID-19) Exposure in Pregnancy,Female,18.0,No,,,,Cohort
NCT04355143,2020_18,Phase 2,Interventional,Colchicine to Reduce Myocardial Injury in COVID-19 (COLHEART-19),All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04350450,2020_18,Phase 2,Interventional,Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore,All,18.0,No,Treatment,Non-Randomized,None (Open Label),Parallel Assignment
NCT04350476,2020_18,,Interventional,COVID-19 Remote Monitoring,All,18.0,No,Screening,,None (Open Label),Single Group Assignment
NCT04343183,2020_18,,Interventional,Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection,All,18.0,No,Treatment,Randomized,Single,Parallel Assignment
NCT04311697,2020_18,Phase 2,Interventional,Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04351620,2020_18,Phase 1,Interventional,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04341935,2020_18,Phase 4,Interventional,Effects of DPP4 Inhibition on COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04361123,2020_18,,Observational,Atrium COVID-19 Syndromic and Serologic Surveillance,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04344600,2020_18,Phase 2,Interventional,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection,All,18.0,No,Prevention,Randomized,Single,Parallel Assignment
NCT04362813,2020_18,Phase 3,Interventional,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04371393,2020_18,Phase 3,Interventional,MSCs in COVID-19 ARDS,All,18.0,No,Treatment,Randomized,Triple,Parallel Assignment
NCT04361214,2020_18,Phase 1,Interventional,Leflunomide in Mild COVID-19 Patients,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04363203,2020_18,Phase 3,Interventional,VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL),All,18.0,No,Treatment,Randomized,Quadruple,Single Group Assignment
NCT04349371,2020_18,Phase 2,Interventional,Saved From COVID-19,All,18.0,No,Prevention,Randomized,Quadruple,Parallel Assignment
NCT04355897,2020_18,Early Phase 1,Interventional,CoVID-19 Plasma in Treatment of COVID-19 Patients,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04346628,2020_18,Phase 2,Interventional,Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04351152,2020_18,Phase 3,Interventional,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia,All,18.0,No,Prevention,Randomized,Double,Parallel Assignment
NCT04351243,2020_18,Phase 2,Interventional,A Study to Assess the Efficacy and Safety of of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04335084,2020_18,Phase 2,Interventional,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",All,18.0,Accepts Healthy Volunteers,Prevention,,None (Open Label),Single Group Assignment
NCT04370938,2020_18,,Interventional,Provider Burnout During COVID-19,All,18.0,Accepts Healthy Volunteers,Other,Randomized,Single,Parallel Assignment
NCT04368728,2020_18,Phase 1/Phase 2,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults",All,18.0,Accepts Healthy Volunteers,Prevention,Randomized,Triple,Parallel Assignment
NCT04379089,2020_18,,Observational,Neurologic Manifestations of COVID 19 in Children,All,,No,,,,Cohort
NCT04365985,2020_18,Phase 2,Interventional,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,All,18.0,No,Treatment,Randomized,Triple,Factorial Assignment
NCT04370782,2020_18,Phase 4,Interventional,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,All,30.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04367740,2020_18,,Observational,"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19",All,18.0,,,,,Case-Only
NCT04365127,2020_18,Phase 1,Interventional,Progesterone for the Treatment of COVID-19 in Hospitalized Men,Male,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04358003,2020_18,,Interventional,Plasma Adsorption in Patients With Confirmed COVID-19,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04356937,2020_18,Phase 3,Interventional,Efficacy of Tocilizumab on Patients With COVID-19,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04360954,2020_18,,Observational,Evaluation of Antibody Tests for COVID-19,All,18.0,,,,,Case-Only
NCT04371315,2020_18,,Observational,"Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children",All,,No,,,,Other
NCT04359797,2020_18,,Interventional,COVID-19 Patient Positioning Pragmatic Trial,All,18.0,No,Supportive Care,Randomized,Single,Parallel Assignment
NCT04370821,2020_18,,Observational [Patient Registry],"COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers",All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04363450,2020_18,Phase 3,Interventional,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),All,18.0,Accepts Healthy Volunteers,Prevention,Randomized,Quadruple,Parallel Assignment
NCT04362865,2020_18,,Observational,Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04363437,2020_17,Phase 2,Interventional,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04346615,2020_17,Phase 2/Phase 3,Interventional,Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04355728,2020_17,Phase 1/Phase 2,Interventional,Use of UC-MSCs for COVID-19 Patients,All,18.0,No,Treatment,Randomized,Single,Parallel Assignment
NCT04352946,2020_17,Phase 3,Interventional,HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial,All,18.0,Accepts Healthy Volunteers,Prevention,Randomized,Quadruple,Parallel Assignment
NCT04368260,2020_17,,Interventional,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,All,,Accepts Healthy Volunteers,Other,Non-Randomized,None (Open Label),Parallel Assignment
NCT04380961,2020_17,Phase 2,Interventional,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04360850,2020_17,,Observational,Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic,All,18.0,Accepts Healthy Volunteers,,,,Ecologic or Community
NCT04331899,2020_17,Phase 2,Interventional,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,All,18.0,No,Treatment,Randomized,Single,Parallel Assignment
NCT04373044,2020_17,Phase 2,Interventional,Antiviral Therapy and Baricitinib for the Treatment of Patients With Moderate or Severe COVID-19,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04341675,2020_17,Phase 2,Interventional,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04365153,2020_17,Phase 2,Interventional,Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19,All,18.0,No,Treatment,Randomized,Quadruple,Factorial Assignment
NCT04362176,2020_17,Phase 3,Interventional,Passive Immunity Trial of Nashville II for COVID-19,All,18.0,No,Treatment,Randomized,Triple,Parallel Assignment
NCT04362995,2020_17,,Observational,St. Jude Tracking of Viral and Host Factors Associated With COVID-19,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04379544,2020_17,,Observational [Patient Registry],Prognostic Value of Point of Care Cardiac and Lung Ultrasound in COVID-19,All,18.0,No,,,,Cohort
NCT04366791,2020_17,Phase 1/Phase 2,Interventional,Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04348435,2020_17,Phase 2,Interventional,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",All,,Accepts Healthy Volunteers,Prevention,Randomized,Quadruple,Parallel Assignment
NCT04360278,2020_17,,Observational,Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04369989,2020_16,,Observational,Observational Study of COVID-19 Treatment Efficacy,All,18.0,No,,,,Cohort
NCT04359810,2020_17,Phase 2,Interventional,Plasma Therapy of COVID-19 in Critically Ill Patients,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04348370,2020_17,Phase 4,Interventional,BCG Vaccine for Health Care Workers as Defense Against COVID 19,All,18.0,Accepts Healthy Volunteers,Prevention,Randomized,Double,Parallel Assignment
NCT04342897,2020_17,Phase 2,Interventional,A Study of LY3127804 in Participants With COVID-19,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04339426,2020_17,Phase 2,Interventional,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04359329,2020_17,Phase 2,Interventional,Estrogen Patch for COVID-19 Symptoms,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04363268,2020_17,,Observational,ACCESS A Master Digital Surveillance Protocol for COVID-19,All,18.0,,,,,Cohort
NCT04350073,2020_17,,Interventional,Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID),All,18.0,No,Diagnostic,Non-Randomized,None (Open Label),Parallel Assignment
NCT04349098,2020_16,Phase 2,Interventional,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,All,18.0,No,Treatment,Randomized,Single,Parallel Assignment
NCT04358549,2020_16,Phase 2,Interventional,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04364737,2020_16,Phase 2,Interventional,Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04335552,2020_16,Phase 2,Interventional,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",All,12.0,No,Treatment,Randomized,None (Open Label),Factorial Assignment
NCT04353271,2020_16,Phase 2/Phase 3,Interventional,Trial of Hydroxychloroquine In Covid-19 Kinetics,All,19.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04357041,2020_16,,Observational,"COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being",All,18.0,Accepts Healthy Volunteers,,,,Case-Only
NCT04359277,2020_16,Phase 3,Interventional,A Randomized Trial of Anticoagulation Strategies in COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04348864,2020_16,,Interventional,COVID-19 Antibody Self-testing Using Virtual Point-of-care,All,18.0,Accepts Healthy Volunteers,Diagnostic,Non-Randomized,None (Open Label),Parallel Assignment
NCT04348240,2020_16,,Observational,Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions,All,18.0,No,,,,Cohort
NCT04347226,2020_16,Phase 2,Interventional,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04376034,2020_16,Phase 3,Interventional,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,All,0.0,No,Treatment,Non-Randomized,None (Open Label),Sequential Assignment
NCT04351880,2020_16,,Interventional,Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge,All,18.0,No,Other,Randomized,Single,Parallel Assignment
NCT04344457,2020_16,Phase 1/Phase 2,Interventional,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04354428,2020_16,Phase 2/Phase 3,Interventional,Treatment for COVID-19 in High-Risk Adult Outpatients,All,18.0,Accepts Healthy Volunteers,Treatment,Randomized,Double,Parallel Assignment
NCT04359836,2020_16,,Observational,A Study to Explore the Role of Gut Flora in COVID-19 Infection,All,18.0,Accepts Healthy Volunteers,,,,Other
NCT04357782,2020_16,Phase 1/Phase 2,Interventional,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,All,18.0,No,Treatment,Non-Randomized,None (Open Label),Single Group Assignment
NCT04350593,2020_16,Phase 3,Interventional,Dapagliflozin in Respiratory Failure in Patients With COVID-19,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04347239,2020_16,Phase 2,Interventional,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04356443,2020_16,,Observational,Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection,All,18.0,No,,,,Cohort
NCT04339998,2020_16,,Observational,Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS),All,18.0,No,,,,Cohort
NCT04342169,2020_16,Phase 2,Interventional,University of Utah COVID-19 Hydrochloroquine Trial,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04357574,2020_16,,Observational,Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19,All,18.0,No,,,,Other
NCT04345653,2020_16,Phase 2,Interventional,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,All,18.0,Accepts Healthy Volunteers,Prevention,,None (Open Label),Single Group Assignment
NCT04344015,2020_16,,Interventional,COVID-19 Plasma Collection,All,18.0,No,Other,,None (Open Label),Single Group Assignment
NCT04326426,2020_16,Phase 3,Interventional,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,All,18.0,No,Treatment,Randomized,Triple,Parallel Assignment
NCT04331886,2020_16,,Observational,An Observational Study of Patients With Coronavirus Disease 2019,All,18.0,No,,,,Cohort
NCT04312009,2020_16,Phase 2,Interventional,Losartan for Patients With COVID-19 Requiring Hospitalization,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04329533,2020_16,,Interventional,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Female,18.0,Accepts Healthy Volunteers,Supportive Care,Randomized,None (Open Label),Parallel Assignment
NCT04343690,2020_16,,Interventional,COPING With COVID-19( CWC-19),All,18.0,Accepts Healthy Volunteers,Other,,None (Open Label),Single Group Assignment
NCT04333654,2020_15,Phase 1,Interventional,Hydroxychloroquine in Outpatient Adults With COVID-19,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04341116,2020_15,Phase 1/Phase 2,Interventional,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04349410,2020_15,Phase 2/Phase 3,Interventional,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,All,,No,Treatment,Randomized,Single,Factorial Assignment
NCT04343261,2020_15,Phase 2,Interventional,Convalescent Plasma in the Treatment of COVID 19,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04349202,2020_15,,Observational,Beaumont Health Large-scale Automated Serologic Testing for COVID-19,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04340050,2020_15,Early Phase 1,Interventional,COVID-19 Convalescent Plasma,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04342637,2020_15,,Observational,COVID-19 Endoscopy Survey,All,30.0,No,,,,Cohort
NCT04342663,2020_15,Phase 2,Interventional,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",All,18.0,No,Treatment,Randomized,Triple,Parallel Assignment
NCT04342806,2020_15,,Observational [Patient Registry],"Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19",All,18.0,,,,,Cohort
NCT04344444,2020_15,Phase 3,Interventional,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04359901,2020_15,Phase 2,Interventional,Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04378595,2020_15,,Observational,Assessing Pediatric Food Insecurity During the COVID-19 Pandemic in Austin,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04377581,2020_15,,Observational,"COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior",All,18.0,Accepts Healthy Volunteers,,,,Ecologic or Community
NCT04311177,2020_15,Phase 2,Interventional,Losartan for Patients With COVID-19 Not Requiring Hospitalization,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04343755,2020_15,Phase 2,Interventional,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04358029,2020_15,,Observational,Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19),All,,No,,,,Case-Only
NCT04329923,2020_15,Phase 2,Interventional,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),All,18.0,Accepts Healthy Volunteers,Treatment,Randomized,Triple,Parallel Assignment
NCT04344236,2020_15,Phase 2,Interventional,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04365699,2020_15,Phase 2,Interventional,Cardiovascular Effects of COVID-19,All,18.0,No,Treatment,Non-Randomized,None (Open Label),Single Group Assignment
NCT04359602,2020_15,,Observational [Patient Registry],COVID-19 Recovered Volunteer Research Participant Pool Registry,All,18.0,No,,,,Case-Only
NCT04317040,2020_15,Phase 3,Interventional,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04344535,2020_15,Phase 1/Phase 2,Interventional,Convalescent Plasma vs. Standard Plasma for COVID-19,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04331366,2020_15,,Interventional,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,All,18.0,No,Supportive Care,,None (Open Label),Single Group Assignment
NCT04373148,2020_15,,Observational,"Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19",All,18.0,Accepts Healthy Volunteers,,,,Case-Control
NCT04342884,2020_15,,Observational,COVID-19 Community Research Partnership,All,,Accepts Healthy Volunteers,,,,Cohort
NCT04342728,2020_15,,Interventional,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,All,18.0,No,Supportive Care,Randomized,None (Open Label),Single Group Assignment
NCT04360538,2020_15,,Observational,Long Term Outcomes of Patients With COVID-19,All,18.0,No,,,,Cohort
NCT04345614,2020_15,Phase 2,Interventional,A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04372472,2020_15,,Observational,SQuISH-COVID: A Pilot Study,All,18.0,No,,,,Cohort
NCT04341441,2020_15,Phase 3,Interventional,Will Hydroxychloroquine Impede or Prevent COVID-19,All,18.0,Accepts Healthy Volunteers,Prevention,Randomized,Triple,Parallel Assignment
NCT04336215,2020_15,,Observational,Rutgers COVID-19 Cohort Study,All,20.0,Accepts Healthy Volunteers,,,,Cohort
NCT04339634,2020_15,,Observational,Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy,All,55.0,No,,,,Cohort
NCT04370262,2020_15,Phase 3,Interventional,Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19,All,18.0,No,Treatment,Randomized,Triple,Parallel Assignment
NCT04328012,2020_15,Phase 2/Phase 3,Interventional,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04328467,2020_15,Phase 3,Interventional,Pre-exposure Prophylaxis for SARS-Coronavirus-2,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04337762,2020_15,,Observational,Beat COVID-19 - Observational Trial,All,18.0,,,,,Case-Control
NCT04332081,2020_15,,Interventional,Hyperbaric Oxygen for COVID-19 Patients,All,18.0,No,Treatment,Non-Randomized,None (Open Label),Single Group Assignment
NCT04329897,2020_14,,Interventional,Acceptance and Commitment Therapy Delivered by Automated Software Messaging,All,18.0,Accepts Healthy Volunteers,Supportive Care,Randomized,None (Open Label),Parallel Assignment
NCT04331795,2020_14,Phase 2,Interventional,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",All,18.0,No,Treatment,Non-Randomized,None (Open Label),Single Group Assignment
NCT04341727,2020_14,Phase 3,Interventional,"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection",All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04354870,2020_14,Phase 2,Interventional,COVID-19 PrEP HCW HCQ Study,All,18.0,No,Treatment,Non-Randomized,None (Open Label),Parallel Assignment
NCT04333225,2020_14,Phase 2,Interventional,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,All,18.0,Accepts Healthy Volunteers,Prevention,Non-Randomized,None (Open Label),Parallel Assignment
NCT04335630,2020_14,,Observational,Cardiovascular Manifestations of COVID-19,All,18.0,No,,,,Case-Control
NCT04379661,2020_14,,Interventional,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,All,18.0,No,Supportive Care,Non-Randomized,None (Open Label),Parallel Assignment
NCT04336410,2020_14,Phase 1,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers",All,18.0,Accepts Healthy Volunteers,Prevention,Non-Randomized,None (Open Label),Sequential Assignment
NCT04320615,2020_14,Phase 3,Interventional,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04368065,2020_14,,Observational [Patient Registry],Registry to Study Factors That May Impact COVID-19 Occurrence and Severity,All,18.0,,,,,Cohort
NCT04332991,2020_14,Phase 3,Interventional,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04325906,2020_14,,Interventional,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04343651,2020_14,Phase 2,Interventional,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04336332,2020_14,Phase 2,Interventional,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04333953,2020_14,,Observational [Patient Registry],COVID-19 in Patients With HIV,All,,No,,,,Case-Only
NCT04343898,2020_14,,Observational,Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19,All,18.0,No,,,,Cohort
NCT04358536,2020_14,,Observational,Classification of COVID-19 Infection in Posteroanterior Chest X-rays,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04358510,2020_14,,Observational,COVID-19 Mortality Prediction Model,All,18.0,No,,,,Cohort
NCT04328961,2020_14,Phase 2/Phase 3,Interventional,Hydroxychloroquine for COVID-19 PEP,All,18.0,Accepts Healthy Volunteers,Prevention,Randomized,Double,Parallel Assignment
NCT04338009,2020_14,,Interventional,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,All,18.0,No,Treatment,Randomized,Single,Parallel Assignment
NCT04343989,2020_14,Phase 2,Interventional,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04323787,2020_14,,Observational,Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry,All,,No,,,,Cohort
NCT04334967,2020_14,Phase 4,Interventional,Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care,All,45.0,No,Treatment,Randomized,Single,Parallel Assignment
NCT04329832,2020_14,Phase 2,Interventional,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04318444,2020_13,Phase 2/Phase 3,Interventional,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),All,18.0,Accepts Healthy Volunteers,Prevention,Randomized,Quadruple,Parallel Assignment
NCT04347993,2020_13,,Observational [Patient Registry],"A Prospective 'Universal'"" Observational Database for COVID-19""",All,,No,,,,Case-Only
NCT04352764,2020_13,,Observational [Patient Registry],ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings,All,,Accepts Healthy Volunteers,,,,Case-Control
NCT04340557,2020_13,Phase 4,Interventional,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,All,18.0,No,Prevention,Randomized,None (Open Label),Parallel Assignment
NCT04326452,2020_13,,Interventional,Treating COVID-19 With a Bidirectional Oxygenation Valve,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04345692,2020_13,Phase 3,Interventional,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04342195,2020_13,,Observational,Acquiring Convalescent Specimens for COVID-19 Antibodies,All,18.0,No,,,,Case-Only
NCT04335123,2020_13,Phase 1,Interventional,Study of Open Label Losartan in COVID-19,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04327804,2020_13,,Observational,A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research,All,,,,,,Case-Only
NCT04326309,2020_13,,Observational,Audio Data Collection for Identification and Classification of Coughing,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04326036,2020_13,Early Phase 1,Interventional,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,All,18.0,No,Treatment,Non-Randomized,None (Open Label),Parallel Assignment
NCT04322682,2020_13,Phase 3,Interventional,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),All,40.0,No,Treatment,Randomized,Single,Parallel Assignment
NCT04339387,2020_9,,Observational,COVID-19 Risk Stratification,All,18.0,No,,,,Cohort
NCT04320472,2020_13,,Observational [Patient Registry],Acute Encephalopathy in Critically Ill Patients With COVID-19,All,18.0,,,,,Cohort
NCT04331509,2020_13,,Observational,COVID-19 Symptom Tracker,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT04319445,2020_12,,Interventional,Mindfulness During COVID-19,All,,Accepts Healthy Volunteers,Other,,None (Open Label),Single Group Assignment
NCT04321811,2020_12,,Observational [Patient Registry],"Behavior, Environment And Treatments for Covid-19",All,18.0,,,,,Cohort
NCT04306393,2020_12,Phase 2,Interventional,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,All,18.0,No,Treatment,Randomized,Single,Parallel Assignment
NCT04305457,2020_12,Phase 2,Interventional,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,All,18.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04376515,2020_12,,Interventional,Harnessing Online Peer Education Online Support Intervention for COVID-19 (HOPE COVID-19),All,18.0,Accepts Healthy Volunteers,Supportive Care,Randomized,Single,Parallel Assignment
NCT04323839,2020_12,,Observational [Patient Registry],COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY),Female,13.0,No,,,,Cohort
NCT04319731,2020_12,Early Phase 1,Interventional,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT04280705,2020_8,Phase 3,Interventional,Adaptive COVID-19 Treatment Trial (ACTT),All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04373161,2020_12,,Interventional,Home Pulse Oximeter Use in Patients With COVID-19,All,18.0,No,Diagnostic,,None (Open Label),Single Group Assignment
NCT04315298,2020_12,Phase 2/Phase 3,Interventional,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04308668,2020_12,Phase 3,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,All,18.0,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT04354701,2020_12,,Observational [Patient Registry],COVID-19 and Cancer Consortium Registry,All,18.0,Accepts Healthy Volunteers,,,,Case-Only
NCT04292730,2020_11,Phase 3,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,All,12.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04374071,2020_11,,Observational,Early Short Course Corticosteroids in COVID-19,All,18.0,No,,,,Cohort
NCT04321369,2020_11,,Observational,Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals,All,,No,,,,Case-Only
NCT04292899,2020_10,Phase 3,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19),All,12.0,No,Treatment,Randomized,None (Open Label),Parallel Assignment
NCT04278404,2020_10,,Observational,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)",All,,Accepts Healthy Volunteers,,,,Other
NCT03852537,2019_49,Phase 2,Interventional,Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia,All,18.0,No,Treatment,Randomized,Double,Parallel Assignment
NCT04341012,2019_37,,Observational,Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases,All,18.0,Accepts Healthy Volunteers,,,,Cohort
NCT03808922,2019_21,Phase 3,Interventional,Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study,All,,No,Treatment,Randomized,Quadruple,Parallel Assignment
NCT03648372,2018_40,Phase 1,Interventional,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)",All,18.0,No,Treatment,,None (Open Label),Single Group Assignment
NCT01306084,2011_9,,Observational,Viral Infections in Healthy and Immunocompromised Hosts,All,,Accepts Healthy Volunteers,,,,Cohort
